Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on <i>Aspergillus fumigatus</i> growth.

ABSTRACT: Fungal infection, especially allergic bronchopulmonary aspergillosis, is a leading cause of infection-associated morbidity and death in patients with cystic fibrosis. We have previously discovered that the new leading treatment in cystic fibrosis, CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor (ETI, Trikafta), drastically reduces the colonization and infection by Aspergillus fumigatus. However, the reasons for this decrease in patients are not known so far. In this study, we have shown, using A. fumigatus reference strains and strains isolated from patients with cystic fibrosis, that CFTR modulators have no discernible impact on initial conidia growth in vitro. However, in a condition-dependent manner, we demonstrated a decrease in the minimal effective concentration

SUBMITTER: Biquand E 

PROVIDER: S-EPMC12403852 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature